Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

被引：0
|
作者：
C. I. Müller
K. Schulmann
A. Reinacher-Schick
N. Andre
D. Arnold
A. Tannapfel
H. Arkenau
S. A. Hahn
S. H.-J. Schmoll
R. Porschen
W. Schmiegel
U. Graeven
机构：
[1] University Hospital Essen,Institute of Physiology
[2] Ruhr-University of Bochum,Medical Department
[3] Martin Luther University,Medical Department IV, University Clinic
[4] Ruhr-University of Bochum,Institute of Pathology, University Clinic Bergmannsheil
[5] Royal Marsden Hospital and Institute of Cancer Research,Drug Development Unit
[6] Ruhr-University of Bochum,Center for Clinical Research (ZKF, Molecular GI
[7] Medical Department Klinikum Bremen-Ost,Oncology (MGO))
[8] Ruhr-University of Bochum,Division of Gastroenterology and Hepatology, University Hospital Bergmannsheil
[9] Kliniken Maria Hilf GmbH Klinik für Hämatologie,undefined
[10] Onkologie,undefined
[11] Gastroenterologie,undefined
来源：
International Journal of Colorectal Disease | 2008年 / 23卷
关键词：
Colorectal cancer; Microsatellite instability; Chemotherapy; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1039
页数：6
相关论文
共 50 条
  • [1] Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy.: A report of the AIO Colorectal Study Group
    Mueller, C. I.
    Schulmann, K.
    Reinacher-Schick, A.
    Andre, N.
    Arnold, D.
    Tannapfel, A.
    Arkenau, H.
    Hahn, S. A.
    Schmoll, S. H. -J.
    Porschen, R.
    Schmiegel, W.
    Graeven, U.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (11) : 1033 - 1039
  • [2] Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer
    Liu, Jia
    Wang, Biao
    Fang, Wentong
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (05) : 267 - 270
  • [3] Value of SMAD4 in patients with advanced colorectal cancer (aCRC) receiving an oxaliplatin containing first line chemotherapy - a study of the AIO colorectal cancer group (AIO)
    Munding, J.
    Baraniskin, A.
    Meier, D.
    Porschen, R.
    Arkenau, H.
    Graeven, U.
    Schulmann, K.
    Schmiegel, W.
    Tannapfel, A.
    Reinacher-Schick, A.
    ONKOLOGIE, 2010, 33 : 71 - 72
  • [4] Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy
    Noepel-Duennebacke, S.
    Schulmann, K.
    Reinacher-Schick, A.
    Porschen, R.
    Schmiegel, W.
    Tannapfel, A.
    Graeven, U.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (12): : 1394 - 1401
  • [5] The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab
    Simkens, L. H. J.
    Tol, J.
    Terstappen, L. W. M. M.
    Teerenstra, S.
    Punt, C. J. A.
    Nagtegaal, I. D.
    ANNALS OF ONCOLOGY, 2010, 21 (12) : 2447 - 2448
  • [6] Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
    Reinacher-Schick, Anke
    Schulmann, Karsten
    Modest, Dominik P.
    Bruns, Nina
    Graeven, Ulrich
    Jaworska, Malgorzata
    Greil, Richard
    Porschen, Rainer
    Arnold, Dirk
    Schmiegel, Wolff
    Tannapfel, Andrea
    BMC CANCER, 2012, 12
  • [7] Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
    Anke Reinacher-Schick
    Karsten Schulmann
    Dominik P Modest
    Nina Bruns
    Ulrich Graeven
    Malgorzata Jaworska
    Richard Greil
    Rainer Porschen
    Dirk Arnold
    Wolff Schmiegel
    Andrea Tannapfel
    BMC Cancer, 12
  • [8] Prognostic Value of Reduced SMAD4 Expression in Patients With Metastatic Colorectal Cancer Under Oxaliplatin-Containing Chemotherapy: A Translational Study of the AIO Colorectal Study Group
    Baraniskin, Alexander
    Munding, Johanna
    Schulmann, Karsten
    Meier, Dominik
    Porschen, Rainer
    Arkenau, Hendrik-Tobias
    Graeven, Ullrich
    Schmiegel, Wolff
    Tannapfel, Andrea
    Reinacher-Schick, Anke
    CLINICAL COLORECTAL CANCER, 2011, 10 (01) : 24 - 29
  • [9] Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy
    Graziano, F.
    Ruzzo, A. M.
    Loupakis, F.
    Canestrari, E.
    Santini, D.
    Catalano, V
    Ficarelli, R.
    Mari, D.
    Bisonni, R.
    Masi, G.
    Schiavon, G.
    Safina, V
    Maltese, P.
    Pizzagalli, F.
    Giordani, P.
    Lippe, P.
    Alessandroni, P.
    Giustini, L.
    Falcone, A.
    Tonini, G.
    Silva, R. R.
    Mattioli, R.
    Menichetti, E. T.
    Testa, E.
    Lai, V
    Magnani, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI42 - XI43
  • [10] Exploring the prognostic and predictive value of circulating tumor DNA in patients with advanced colorectal cancer and chemotherapy.
    Liu, Xiu
    Zhang, Xuan
    Ou, Kai
    Lu, Chelong
    Zheng, Dong
    Liu, Jun
    Xu, Qiang
    Yang, Lin
    CANCER RESEARCH, 2021, 81 (13)
12345